{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:58:59Z","timestamp":1790611139152,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03720-2","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T05:22:25Z","timestamp":1784697745000},"page":"4793-4811","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Budget Impact of Eplerenone for Heart Failure with Reduced Ejection Fraction: National Perspective and Regional Implications in Italy"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0971-4558","authenticated-orcid":false,"given":"Giuseppe","family":"Pompilio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Bellomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco Maria","family":"Pio Mondello Malvestiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0369-2052","authenticated-orcid":false,"given":"Nadia","family":"Aspromonte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"issue":"1","key":"3720_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","volume":"3","author":"G Savarese","year":"2017","unstructured":"Savarese G, Lund LH. Global public health burden of heart failure. Card Fail Rev. 2017;3(1):7\u201311. https:\/\/doi.org\/10.15420\/cfr.2016:25:2.","journal-title":"Card Fail Rev"},{"issue":"36","key":"3720_CR2","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368.","journal-title":"Eur Heart J"},{"issue":"37","key":"3720_CR3","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339. https:\/\/doi.org\/10.1093\/eurheartj\/ehad195.","journal-title":"Eur Heart J"},{"issue":"13","key":"3720_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.029071","volume":"12","author":"D D\u2019Amario","year":"2023","unstructured":"D\u2019Amario D, Rodolico D, Delvinioti A, et al. Eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge. J Am Heart Assoc. 2023;12(13):e029071. https:\/\/doi.org\/10.1161\/JAHA.122.029071.","journal-title":"J Am Heart Assoc"},{"key":"3720_CR5","doi-asserted-by":"publisher","DOI":"10.26402\/jpp.2018.6.01","author":"D Sztechman","year":"2018","unstructured":"Sztechman D, Czarzasta K, Cudnoch-Jedrzejewska A, Szczepanska-Sadowska E, Zera T. Aldosterone and mineralocorticoid receptors in regulation of the cardiovascular system and pathological remodelling of the heart and arteries. J Physiol Pharmacol. 2018. https:\/\/doi.org\/10.26402\/jpp.2018.6.01.","journal-title":"J Physiol Pharmacol"},{"key":"3720_CR6","unstructured":"Agenzia Italiana del Farmaco (AIFA). RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO - Spironolattone."},{"key":"3720_CR7","unstructured":"Agenzia Italiana del Farmaco (AIFA). RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO - Canrenone."},{"issue":"16","key":"3720_CR8","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","volume":"391","author":"SD Solomon","year":"2024","unstructured":"Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391(16):1475\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2407107.","journal-title":"N Engl J Med"},{"issue":"14","key":"3720_CR9","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309\u201321. https:\/\/doi.org\/10.1056\/NEJMoa030207.","journal-title":"N Engl J Med"},{"issue":"1","key":"3720_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492.","journal-title":"N Engl J Med"},{"key":"3720_CR11","unstructured":"Agenzia Italiana del Farmaco (AIFA). RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO - Eplerenone [Internet]. https:\/\/medicinali.aifa.gov.it\/it\/#\/it\/dettaglio\/0000038969. Accessed 14 Dec 2025."},{"issue":"5","key":"3720_CR12","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"JA Mauskopf","year":"2007","unstructured":"Mauskopf JA, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices\u2013budget impact analysis. Value Health. 2007;10(5):336\u201347. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00187.x.","journal-title":"Value Health"},{"issue":"1","key":"3720_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jval.2013.08.2291","volume":"17","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Health. 2014;17(1):5\u201314. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291.","journal-title":"Value Health"},{"key":"3720_CR14","unstructured":"Istituto Nazionale di Statistica. Popolazione residente al 1\u00b0 gennaio 2025 [Internet]. https:\/\/demo.istat.it\/app\/?i=POS&l=it. Accessed 9 Jan 2026."},{"key":"3720_CR15","unstructured":"Ministero della Salute, Alleanza per le malattie cardio-cerebrovascolari. Aderenza terapeutica: analisi critica e prospettive per un percorso efficace di cura delle malattie cardio-cerebrovascolari [Internet]. 2024. https:\/\/fondazionecuore.it\/wp-content\/uploads\/2024\/09\/Aderenza_Terapeutica_Alleanza_MCC.pdf. Accessed 23 Nov 2025."},{"key":"3720_CR16","unstructured":"Population and household projections \u2013 Base 1\/1\/2024 [Internet]. https:\/\/www.istat.it\/en\/press-release\/population-and-household-projections-base-1-1-2024\/. Accessed 2025 Aug 26."},{"issue":"17","key":"3720_CR17","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","volume":"118","author":"G Savarese","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GMC, Coats AJS. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023;118(17):3272\u201387. https:\/\/doi.org\/10.1093\/cvr\/cvac013.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"3720_CR18","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ehf2.13144","volume":"8","author":"D Jen\u010da","year":"2021","unstructured":"Jen\u010da D, Melenovsk\u00fd V, Stehlik J, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021;8(1):222\u201337. https:\/\/doi.org\/10.1002\/ehf2.13144.","journal-title":"ESC Heart Fail"},{"issue":"2","key":"3720_CR19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40292-017-0193-4","volume":"24","author":"C Piccinni","year":"2017","unstructured":"Piccinni C, Antonazzo IC, Simonetti M, et al. The burden of chronic heart failure in primary care in Italy. High Blood Press Cardiovasc Prev. 2017;24(2):171\u20138. https:\/\/doi.org\/10.1007\/s40292-017-0193-4.","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"16","key":"3720_CR20","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1161\/CIR.0b013e31829e8776","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Writing Committee Members, Yancy CW, Jessup M, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-327. https:\/\/doi.org\/10.1161\/CIR.0b013e31829e8776.","journal-title":"Circulation"},{"key":"3720_CR21","unstructured":"Agenzia Italiana del Farmaco (AIFA). Liste di trasparenza [Internet]. https:\/\/www.aifa.gov.it\/liste-di-trasparenza. Accessed 15 Jan 2026."},{"issue":"7","key":"3720_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102615","volume":"49","author":"K Pamporis","year":"2024","unstructured":"Pamporis K, Karakasis P, Sagris M, et al. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials. Curr Probl Cardiol. 2024;49(7):102615. https:\/\/doi.org\/10.1016\/j.cpcardiol.2024.102615.","journal-title":"Curr Probl Cardiol"},{"key":"3720_CR23","doi-asserted-by":"publisher","first-page":"94","DOI":"10.33393\/grhta.2024.3013","volume":"11","author":"M Dovizio","year":"2024","unstructured":"Dovizio M, Leogrande M, Esposti LD. Scompenso cardiaco e impatto economico: un\u2019analisi nella reale pratica clinica in Italia. Glob Reg Health Technol Assess. 2024;11:94\u2013100. https:\/\/doi.org\/10.33393\/grhta.2024.3013.","journal-title":"Glob Reg Health Technol Assess"},{"key":"3720_CR24","unstructured":"Ministero della Salute. Tariffe delle prestazioni di assistenza ospedaliera per acuti, per tipo di ricovero (\u20ac) [Internet]. https:\/\/www.salute.gov.it\/portale\/assistenzaOspedaliera\/dettaglioContenutiAssistenzaOspedaliera.jsp?lingua=italiano&id=1349&area=ricoveriOspedalieri&menu=vuoto. Accessed 16 Dec 2025."},{"issue":"1","key":"3720_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12962-024-00547-y","volume":"22","author":"E Stawowczyk","year":"2024","unstructured":"Stawowczyk E, Ward T, Paoletti E, Senni M, de Arellano AR. Hyperkalemia in chronic kidney disease patients with and without heart failure: an Italian economic modelling study. Cost Eff Resour Alloc CE. 2024;22(1):42. https:\/\/doi.org\/10.1186\/s12962-024-00547-y.","journal-title":"Cost Eff Resour Alloc CE"},{"key":"3720_CR26","unstructured":"Ministero della Salute. Tariffe delle prestazioni di assistenza specialistica ambulatoriale [Internet]. https:\/\/www.salute.gov.it\/new\/it\/tema\/programmazione-e-finanziamento-del-ssn\/tariffari-nazionali-delle-prestazioni-del-ssn\/?paragraph=0#body. Accessed 16 Dec 2025."},{"issue":"8","key":"3720_CR27","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/ejhf.1793","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol P, Lainscak M, Crespo-Leiro MG, et al. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2020;22(8):1378\u201389. https:\/\/doi.org\/10.1002\/ejhf.1793.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"3720_CR28","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. 30\u00a0years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60\u00a0years of research and development. J Endocrinol. 2017;234(1):T125\u201340. https:\/\/doi.org\/10.1530\/JOE-16-0600.","journal-title":"J Endocrinol"},{"issue":"6","key":"3720_CR29","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/andr.12636","volume":"7","author":"GA Kanakis","year":"2019","unstructured":"Kanakis GA, Nordkap L, Bang AK, et al. EAA clinical practice guidelines-gynecomastia evaluation and management. Andrology. 2019;7(6):778\u201393. https:\/\/doi.org\/10.1111\/andr.12636.","journal-title":"Andrology"},{"key":"3720_CR30","doi-asserted-by":"crossref","unstructured":"McKenna C, Burch J, Suekarran S, et al. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure. In: NIHR Health Technology Assessment programme: Executive Summaries [Internet]. NIHR Journals Library; 2010. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK56872\/. Accessed 2025 Aug 26.","DOI":"10.3310\/hta14240"},{"issue":"19","key":"3720_CR31","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1161\/CIR.0b013e3181f9a223","volume":"122","author":"NL Weintraub","year":"2010","unstructured":"Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims. Circulation. 2010;122(19):1975\u201396. https:\/\/doi.org\/10.1161\/CIR.0b013e3181f9a223.","journal-title":"Circulation"},{"issue":"12","key":"3720_CR32","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1177\/2047487319833507","volume":"26","author":"RS Taylor","year":"2019","unstructured":"Taylor RS, Sadler S, Dalal HM, et al. The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared with the usual medical care for heart failure with reduced ejection fraction: a decision model-based analysis. Eur J Prev Cardiol. 2019;26(12):1252\u201361. https:\/\/doi.org\/10.1177\/2047487319833507.","journal-title":"Eur J Prev Cardiol"},{"issue":"37","key":"3720_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/QOVK6659","volume":"29","author":"H Mistry","year":"2022","unstructured":"Mistry H, Enderby J, Court R, et al. Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom. Health Technol Assess. 2022;29(37):1\u201361. https:\/\/doi.org\/10.3310\/QOVK6659.","journal-title":"Health Technol Assess"},{"issue":"21","key":"3720_CR34","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1002\/sim.6530","volume":"34","author":"LM Kunz","year":"2015","unstructured":"Kunz LM, Normand SLT, Marinac-Dabic D, Sedrakyan A. Meta-analysis of rate ratios with differential follow-up by treatment arm: inferring comparative effectiveness of medical devices. Stat Med. 2015;34(21):2913\u201325. https:\/\/doi.org\/10.1002\/sim.6530.","journal-title":"Stat Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03720-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03720-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:39:41Z","timestamp":1790609981000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03720-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3720"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03720-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Giuseppe Pompilio and Claudio Bellomo are employees of Viatris Italia S.r.l. and have nothing else to disclose. Franco Maria Pio Mondello Malvestiti was an employee of Viatris at the time of the study and is now retired; he has nothing else to disclose. Nadia Aspromonte received no financial compensation for her involvement in this study and has nothing to disclose.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}